More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy

Rheumatology (United Kingdom)

Volumn 56, Issue 5, 2017, Pages 787-794

  Tiniakou, Eleni ^a   Pinal Fernandez, Iago ^b   Lloyd, Thomas E ^a   Albayda, Jemima ^a   Paik, Julie ^a   Werner, Jessie L ^a   Parks, Cassie A ^b   Casciola Rosen, Livia ^a   Christopher Stine, Lisa ^a   Mammen, Andrew L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Autoantibodies; Myopathy; Polymyositis

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A ANTIBODY; CORTICOSTEROID; CREATINE KINASE; ENZYME ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHOTREXATE; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOPATHY; CANCER RISK; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MALE; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; ONSET AGE; PRIORITY JOURNAL; WHOLE EXOME SEQUENCING; ADOLESCENT; AFTERCARE; AGED; CHILD; CONVALESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM; PHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SKELETAL MUSCLE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFTERCARE; AGE OF ONSET; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; CREATINE KINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSITIS; NEOPLASMS; PROGNOSIS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 85019729351     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew470     Document Type: Article

References (20)

1. Christopher-Stine L, Casciola-Rosen LA, Hong G et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757-66
2. Mammen AL, Chung T, Christopher-Stine L et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-21
3. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med 2016;374:664-9
4. Mammen AL, Pak K, Williams EK et al. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects. Arthritis Care Res 2011;64:269-72
5. Werner JL, Christopher-Stine L, Ghazarian SR et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64:4087-93
6. Kaplan JC, Hamroun D. The 2015 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord 2014;24:1123-53
7. Pinal-Fernandez I, Parks C, Werner JL et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res 2016; Advance Access published 23 April 2016, doi: 10.1002/acr.22920
8. Mammen AL, Casciola-Rosen L, Christopher-Stine L, Lloyd TE, Wagner KR. Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e172
9. Claeys KG, Gorodinskaya O, Handt S et al. Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology 2013;81:932-5
10. Klein M, Mann H, Plestilova L et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology 2015;54:2010-4
11. Limaye V, Bundell C, Hollingsworth P et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015;52:196-203
12. Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 2015;72:996-1003
13. Allenbach Y, Drouot L, Rigolet A et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine 2014;93:150-7
14. Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 2015;10:e0141616
15. Watanabe Y, Uruha A, Suzuki S et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016;87:1038-44
16. Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015;2:e124
17. Alarcon J, Aguila S, Arancibia-Avila P et al. Production and purification of statins from Pleurotus ostreatus (Basidiomycetes) strains. Z Naturforsch C 2003;58:62-4
18. Allenbach Y, Keraen J, Bouvier AM et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016;139:2131-5
19. Rider LG, Werth VP, Huber AM et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 2011;63 (Suppl 11):S118-57
20. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24